- For Print
- June 8, 2017
Pfizer Japan Inc.
°®¶¹´«Ã½.
Pfizer Japan Inc. (Headquarters: Tokyo, President and Representative Director: Ichiro Umeda, “Pfizer”) and °®¶¹´«Ã½. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) have announced that Lyrica® OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin), will be launched on June 8.
Lyrica Capsules are co-promoted in Japan by Pfizer and Eisai, with both companies working to provide information on its proper use. Likewise, Lyrica OD Tablets will also be co-promoted by both companies in Japan.
Lyrica is indicated for use in patients with neuropathic pain and pain associated with fibromyalgia. Many of these patients are elderly, and there are cases of patients having difficulty swallowing. Lyrica OD Tablets dissolve swiftly inside the mouth, making it an easy form for these patients to take, and are expected to lead to increased convenience when taking medicine.
Through Lyrica, Pfizer and Eisai will continue to contribute to improvement of quality of life in patients suffering from neuropathic pain and pain associated with fibromyalgia.
°®¶¹´«Ã½. Public Relations Department
Pain Treatment Lyrica OD Tablets Outline
*You can scroll to the left or right here
Product Name: | Lyrica® OD Tablet 25mg•75mg•150mg |
---|---|
Generic Name: | Pregabalin |
Approval Date: | February 17, 2017 |
NHI Price Listing Date | May 31, 2017 |
Launch Date | June 8, 2017 |
Manufactured and Marketed by: | Pfizer Japan Inc. |
Co-promoted by: | °®¶¹´«Ã½. |
Indications and Usage | Neuropathic pain, Pain associated with fibromyalgia |
Dosage and Administration | Neuropathic pain Pain associated with fibromyalgia |
Price | Lyrica OD Tablet 25mg: 67.80 yen Lyrica OD Tablet 75mg: 112.90 yen Lyrica OD Tablet 150mg: 155.00 yen |
Packaging | Lyrica OD Tablet 25mg: 100 tablets (PTP), 500 tablets (PTP) Lyrica OD Tablet 75mg: 100 tablets (PTP), 500 tablets (PTP) Lyrica OD Tablet 150mg: 100 tablets (PTP) |